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When  natural  bone  repair  mechanisms  fail,  autologous  bone  grafting  is the  current  standard  of  care.
The  osteogenic  cells  and  bone  matrix  in  the  graft  provide  the  osteo-inductive  and  osteo-conductive
properties  required  for  successful  bone  repair.  Bone  marrow  (BM)  mesenchymal  stem  cells  (MSCs)  can
differentiate  into  osteogenic  cells.  MSC-based  cell  therapy  holds  promise  for  promoting  bone  repair.
The  amount  of  MSCs  available  from  iliac-crest  aspirates  is too  small  to be  clinically  useful,  and  either
concentration  or culture  must  therefore  be  used  to  expand  the  MSC  population.  MSCs  can  be administered
alone  via  percutaneous  injection  or implanted  during  open  surgery  with  a biomaterial,  usually  biphasic
hydroxyapatite/-calcium-triphosphate  granules.  Encouraging  preliminary  results  have  been obtained  in
patients  with  delayed  healing  of  long  bone  fractures  or avascular  necrosis  of  the  femoral  head.  Bone  tissue
engineering  involves  in  vitro  MSC  culturing  on  biomaterials  to obtain  colonisation  of the  biomaterial  and
differentiation  of  the  cells.  The  biomaterial-cell  construct  is  then  implanted  into  the  zone  to be treated.
Few  published  data  are  available  on  bone tissue  engineering.  Much  work  remains  to  be done  before
determining  whether  this  method  is suitable  for  the routine  ﬁlling  of  bone  tissue  defects.  Increasing  cell
survival  and  promoting  implant  vascularisation  are  major  challenges.  Improved  expertise  with  culturing
techniques,  together  with  the incorporation  of regulatory  requirements,  will  open  the way  to  high-quality
clinical  trials  investigating  the  usefulness  of cell therapy  as a method  for achieving  bone  repair.  Cell
therapy  avoids  the  drawbacks  of  autologous  bone  grafting,  preserving  the  bone  stock  and  diminishing
treatment  invasiveness.Physiological bone repair results in the production of normal
one. Unfavourable local conditions (e.g., inadequate blood sup-
ly, soft tissue injury, or mechanical instability) and/or extensive
one tissue loss may  result in failure of physiological bone repair
ith delayed healing, nonunion, or a persistent bone defect. In
hese situations, autologous bone grafting is the current standard of
are. The osteogenic cells and bone matrix in the graft provide the
steo-inductive and osteo-conductive properties required for new
one formation. However, drawbacks of autologous bone grafting
nclude donor-site morbidity [1], limited availability of autologous
one, and loss of bone stock. Attention has therefore turned to
ther options, such as allogeneic bone grafts and bone substitutes,
hich supply an osteo-conductive matrix. Cytokines, most notably
one morphogenetic proteins (BMPs) can be added to produce
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osteo-inductive effects. Physical methods (e.g., electromagnetic
ﬁelds and ultrasounds) remain to be evaluated.
Cell therapy holds promise as an alternative to autologous bone
grafting for promoting bone repair. Bone progenitor cells are sup-
plied to the injury site, either alone or in combination with a mineral
or protein matrix and/or cytokines. In bone tissue engineering, the
cells are cultured, alone or on a biomaterial, before implantation.
Cell therapy spares the bone stock and diminishes treatment inva-
siveness.
This conference reviews the current use of cell therapy for
bone repair in humans, chieﬂy at long bone sites, to achieve either
fracture healing or bone defect ﬁlling. Cell therapy for disorders
of bone metabolism (osteoporosis), osteogenesis imperfecta, and
gene therapy will not be discussed.
1. Physiology of bone repairBone tissue is capable of self-repair, which results in the pro-
duction of new bone exhibiting all the characteristics of normal
bone. Fracture healing or bone defect ﬁlling by an autologous can-
cellous bone graft results from interactions among osteogenic cells,
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ytokines, an osteo-conductive matrix, and a mechanically stable
nvironment with a good blood supply, according to the ‘diamond
oncept’ [2].
In rare cases, the cortices undergo primary healing after per-
ect fracture reduction and stabilisation. Usually, however, fracture
ealing involves intra-membranous and enchondral ossiﬁcation.
his complex dynamic process requires the precise orchestration of
arious events during four overlapping stages [3] having distinctive
istological characteristics: an inﬂammatory response, formation
f a cartilaginous soft callus, formation of a bone hard callus, and
one union with remodelling. This process involves a sequence of
nabolic and catabolic events, some of which are non-speciﬁc (pro-
uction then remodelling of the cartilaginous callus) and others
peciﬁc (formation of the bone callus, which is then remodelled into
ormal bone). Thus, bone resorption plays a crucial role, and the
esorption and formation processes are not separate or indepen-
ent in time and space. The ﬁnal result of the bone repair process
s the production by the cells of a collagen matrix, whose ossiﬁca-
ion restores the normal mechanical properties of the bone. These
istologically deﬁned stages of bone repair require a number of cel-
ular events (migration, proliferation, and differentiation), whose
oordination is ensured by cytokines and growth factors.
Inﬂammation plays a role of paramount importance at the
eginning of the bone repair process. The injury triggers the release
f pro-inﬂammatory cytokines (interleukins IL-1 and IL-6, TNF),
hose chemotactic effects attract inﬂammatory cells and stimulate
ngiogenesis at the fracture site. Cell types that are more speciﬁc
o the bone repair process are involved subsequently. Although the
olecular mechanisms that regulate cell proliferation and differ-
ntiation have been partly elucidated, no biological markers of use
or the clinical monitoring of bone healing have been identiﬁed to
ate.
. Cell types involved in bone repair
The bone repair process mobilises many cell types. Despite
aving no direct role in bone formation, the cell types involved
n the inﬂammatory and angiogenic responses are indispensable
o the development of the bone formation mechanisms. They
elease cytokines and growth factors (PDGF, BMPs, VEGF, and inter-
eukins) that attract and activate the mesenchymal stem cells
MSCs) directly involved in bone repair.
MSCs are precursors of osteoprogenitor cells. They play a key
ole in cell therapy for bone repair, as they are the best characterised
ultipotent cells and can now be produced reliably for clinical pur-
oses. The osteoclast lineage makes a major contribution to bone
emodelling but is not currently used for clinical applications.
Friedenstein et al. [4] were the ﬁrst to demonstrate new bone
ormation from cultured bone marrow (BM) cells. The BM cells
roliferated in vitro, generating colonies of ﬁbroblast-like cells,
r ‘colony-forming unit ﬁbroblasts’ (CFU-Fs). MSCs are deﬁned
s multipotent non-haematopoietic cells capable of differentiat-
ng into functional cell types found in various mesenchymatous
issues (bone, cartilage, muscle, tendon, adipose tissue, and haem-
topoietic stroma) [5]. The self-renewal capacity of MSCs ensures
hat they maintain their multipotency throughout their life span.
MSCs can be identiﬁed in vitro based on their ability to adhere
o plastic culture dishes and to generate CFU-Fs after several
ays of culture in standard medium containing foetal calf serum.
hen, depending on the available induction inﬂuences, MSCs can
ifferentiate into bone tissue cells (osteoblasts), cartilage cells
chondrocytes), and adipose cells (adipocytes) [5]. The in vitro MSC
henotype is characterised by absence of expression of membrane
olecules speciﬁc of haematopoietic cells (CD45, CD14, and CD34),
ontrasting with the presence of other molecules (CD73, CD44,urgery & Research 100 (2014) S107–S112
CD105, CD90, and CD146). No marker strictly speciﬁc of MSCs is
available [6], a fact that complicates the reliable identiﬁcation of
MSCs and their extraction from the pool of nucleate BM cells.
MSCs were ﬁrst identiﬁed in BM [5] then in adipose tissue [7],
cord blood, the placenta [8], the periosteum [9], and other tissues.
MSCs from these different sources share similar phenotypic charac-
teristics but differ regarding their differentiation and proliferation
properties. It should be noted that these MSCs are identiﬁed only
after culturing. Native MSCs (naturally found in tissues), in contrast,
are poorly characterised and difﬁcult to identify. Native MSCs have
been identiﬁed in blood vessel walls [10].
The source of the MSCs present at sites of bone repair, partic-
ularly after a fracture, is difﬁcult to determine. In animal models,
these cells come from the periosteum, BM,  and neighbouring soft
tissues. The most obvious source of MSCs is the BM,  in which MSCs
contribute 0.001% to 0.01% of all mononuclear cells in healthy
adults, with a decrease over the life span [11,12]. One millil-
itre of BM contains only 18 ± 7 × 106 mononuclear cells including
612 ± 134 MSCs [13]. BM concentration and culturing techniques
are therefore valuable to expand the MSC  population available for
clinical use.
Methods are now available for expanding MSCs in compliance
with current regulatory requirements for use in clinical applica-
tions [14]. Current culture media contain no animal products and
are based on human platelet lysates designed for optimal safety.
Within 2–3 weeks, a 30-mL sample of iliac-crest BM generates sev-
eral million MSCs, depending on the available culture surface area.
During culturing, MSC  differentiation to cartilage, adipose, or bone
cells can be induced. Acquiring a high level of expertise with MSC
production and differentiation to osteoprogenitor cells is crucial
to successful bone repair. Differentiation of cultured MSCs to the
osteoblastic lineage (osteo-induction) can be obtained by adding
BMP  (BMP2 or BMP4) or dexamethasone.
Differentiating MSCs release growth factors and cytokines that
contribute to regulate the bone repair process. The ﬂuctuations over
time in the production of growth factors and cytokines are poorly
known, a fact that limits our ability to obtain precise therapeutic
effects by using these molecules.
An interesting characteristic of MSCs pertains to the immune
system: MSCs are not immunogenic, because they express little
or no major histocompatibility complex Class II molecules and
induce no T-cell proliferation. On the contrary, MSCs have immuno-
suppressive properties related to their ability to inhibit T-cell
proliferation and NK-cell lysis under allogeneic conditions [15,16].
These properties may  enable allogeneic MSC  transplantation with-
out immunosuppressive therapy of the recipient and suggest a role
for universal MSC  banks for regenerative medicine.
Another major advantage of MSCs is a high level of resilience
with preservation of bone repair capabilities even after several
hours of transport.
3. Cell therapy approaches to bone repair
According to the diamond concept [2], MSCs play a crucial role
in bone repair. Cell therapy can serve as an alternative to autol-
ogous bone grafting. A large number of osteoprogenitor cells are
implanted at the injury site, either alone or combined with a matrix.
BM MSCs are currently the most appropriate cells for inducing bone
repair, as they have a strong osteogenic potential and are easily
obtained by culturing iliac-crest aspirates.
Several MSC-based cell therapy modalities have been devel-
oped, i.e., with and without cell culturing and with or without a
matrix.
The mononuclear cell fraction of the BM,  which contains
the MSCs, can be used directly by percutaneous injection of
P. Rosset et al. / Orthopaedics & Traumatology: Surgery & Research 100 (2014) S107–S112 S109
 cultu
a
a
i
M
m
B
H
f
o
o
(
t
t
M
a
b
bFig. 1. Use of bone marrow or
spirated BM into the injury site. BM is aspirated into hep-
rin syringes, in small fractions of 2–4 mL,  as blood aspirated
n larger fractions dilutes the BM and therefore decreases the
SC concentration [13]. To increase the number of injected
ononuclear cells and consequently of MSCs, the aspirated
M can be concentrated by centrifugation. After concentration,
ernigou et al. [13] obtained 2579 ± 1121 MSCS per mL,  i.e., 3-
old to 6-fold the number obtained after aspiration. Concentrated
r unconcentrated mononuclear cells can be combined intra-
peratively with a synthetic or natural osteo-conducting matrix
e.g., allogeneic bone graft or coral) (Fig. 1) before implanta-
ion.
Mononuclear cells can be cultured in vitro to enable the selec-
ion and expansion of MSCs. This method generates millions of
SCs, whereas only a few thousand are present initially in the
spirate. Cultured MSCs can be injected percutaneously or com-
ined with biomaterials to produce a construct appropriate for
one grafting (Fig. 1).
Fig. 2. Bioreactor principle allowing culturing of mesenchymred mesenchymal stem cells.
MSCs can be cultured in vitro on biomaterials for a few days or
weeks. Biomaterial colonisation and cell differentiation is obtained,
and the construct is then implanted into the injury site. This proce-
dure follows the bioreactor concept used in bone tissue engineering
(Fig. 2).
One option consists in implanting the construct into a muscle
for a few weeks to promote angiogenesis. The muscle containing
the construct is then harvested and transplanted into the injury
site. An anastomosis with the muscle vascular pedicle is created to
ensure an adequate blood supply. Thus, the patient becomes his or
her own  bioreactor [17].
Several biomaterials can be chosen for combination with the
cells, depending on the goal (mechanical strength or ﬁlling)
and approach (percutaneous or surgical). The most widely used
biomaterials are calcium-phosphate ceramics, which usually com-
bine hydroxyapatite and -tricalcium phosphate as granules or,
more rarely, sticks, and exhibit interconnected pores each mea-
suring 100–400 m.  These biomaterials promote the adhesion,
al stem cells on a biomaterial prior to implantation.
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roliferation, and osteoblastic differentiation of MSCs, as well as
he production of the collagen matrix that subsequently undergoes
ineralisation. Collagen sponges and biodegradable polymers can
e used also. The biomaterials must be absorbable, at a variable rate
epending on their anticipated biomechanical role, and must allow
he ingrowth of newly formed blood vessels from the neighbouring
issues. Good-quality vascularisation of the tissue in contact with
he implant is crucial.
. Cell therapy for bone repair in humans
Factors that inﬂuence bone union or bone defect ﬁlling include
he site, defect size, quality of the overlying skin and muscle, and
uality of the blood supply. Translation research from animal bone
epair models to humans remains limited, as detailed in a previous
rticle [18]. Only the most signiﬁcant case-series are discussed here.
.1. Delayed union or nonunion with no bone defect
Delayed union and nonunion are common complications for
hich the current standard of care is autologous cancellous bone
rafting, combined with internal ﬁxation. A muscle ﬂap is used if the
one is exposed. Autologous bone grafting is a form of cell therapy,
ince the graft supplies BM cells including MSCs, as well as bone
atrix.
.1.1. Initial attempts at cell therapy relied on BM alone
One method consisted in aspirating the BM and re-injecting it
ercutaneously. In 1991, Connolly et al. reported a positive cor-
elation between bone union and the cell concentration in the
M aspirates [19]. The treatment was successful in 18 of their
0 patients with tibial nonunion. In a study by Garg et al. [20] in
atients with long bone nonunion treated with two BM injections
 weeks apart, bone union was achieved within 5 months in 17 of
he 20 patients.
Another option consists in concentrating the BM aspirates to
ncrease the number of injected MSCs. In patients with nonunion,
ernigou and Beaujean [21] observed decreased MSC  densities not
nly at the nonunion site, but also in the iliac-crest BM aspirates, a
nding replicated recently by Mathieu et al. [22], who  also reported
ecreased cytokine and growth factor levels. Hernigou et al. [23]
sed BM concentrates prepared from a mean aspirate volume
f 300 mL  and obtained healing of 53/60 (88%) tibial nonunions.
he healing rate increased with the injected MSC  concentration.
atients whose fractures did not heal received fewer than 1000
SCs per mL  and fewer than 30,000 MSCs in all, whereas those
ho healed received signiﬁcantly higher MSC  concentrations and
ounts, with a mean of 1500 MSCs per mL  and 54,000 MSCs in all,
n a volume of 20 mL.
BM concentration can be performed from BM aspirates of
00–500 mL,  by accredited cell therapy laboratories. A fraction of
he recovered mononuclear cells is kept at the laboratory for deter-
ination of the CFU-F count, which reﬂects the MSC concentration
ithin the re-injected mononuclear cells. Concentration of smaller
M samples, performed in the operating room, produces fewer
ononuclear cells, mirroring the smaller initial population, and
oes not allow CFU-F quantiﬁcation to evaluate the number of re-
njected MSCs. This procedure can be used, however, in situations
hat do not require a large number of MSCs.
Few published studies assessed the combined use of concen-
rated or unconcentrated BM with a biomaterial. This method is a
alid option for everyday practice, provided CE-marked biomateri-
ls are used and concentration (if used) is achieved via an approved
rocedure.
Ateschrang et al. [24] studied 15 patients with infected tib-
al nonunion. After eradication of the infection, cancellous boneurgery & Research 100 (2014) S107–S112
allografts vitalised with an injection of autologous BM were
implanted. They obtained infection control in 14 patients and bone
union in 11 patients. Dallari et al. [25] compared bone chips alone,
bone chips with platelet gel, and bone chips with platelet gel and
BM cell concentrates in patients treated with tibial osteotomy for
genu varum. The outcomes were better in the groups that received
platelet gel with or without BM cells.
4.1.2. The MSC  population can be expanded in vitro
During lengthening of 51 femurs or tibias, the use of culture-
expanded MSCs and platelet-rich plasma was  associated with a
signiﬁcant improvement in the healing index compared to 60 con-
trol bones [26]. The healing index was better for the femur than for
the tibia, suggesting a role for the blood supply and soft tissues.
In a prospective randomised trial of 64 closed long bone frac-
tures with delayed healing, callus formation after 2 months was
improved in the group given cultured MSCs compared to the control
group [27].
4.2. Treatment of bone defects
Bone defects are more challenging to treat. The success rate
depends on the size and quality of the adjacent soft tissues. For
bone defects no larger than 2–3 cm,  autologous bone grafting alone
may  be sufﬁcient. A very useful technique for larger defects is the
Masquelet procedure, in which cement is implanted to induce the
formation of a membrane, whose osteo-inductive properties then
promote the union of the autologous cancellous bone graft that is
implanted subsequently. The use of vascularised bone grafts such
as the ﬁbula averts the risk of graft necrosis. The Ilizarov technique
often requires an additional graft at the end of the procedure. Draw-
backs of allografts implanted into large bone defects include partial
re-inhabitation, a risk of absorption, and a risk of infectious agent
transmission.
Percutaneous injection of unconcentrated BM into unicameral
cysts was inferior to glucocorticoid injections in one study [28] and
successful in another [29]. Park et al. [30] compared surgery with
bone chip and autologous BM implantation to percutaneous injec-
tion of allogeneic demineralized bone matrix and autologous BM
in 23 patients with calcaneal unicameral cysts. The outcomes were
similar, with a lower morbidity rate in the percutaneous injection
group.
In a study of 79 acetabular defects with 87% of type III (American
Academy of Orthopaedic Surgeons classiﬁcation) during revision
hip replacement surgery, Ochs et al. [31] obtained similar outcomes
with frozen non-irradiated allografts and with allografts vitalised
by autologous bone marrow after irradiation to eliminate the risk
of pathogen transmission.
Quarto et al. [32] were the ﬁrst to report the use of cultured BM
MSCs combined intra-operatively with hydroxyapatite blocks to ﬁll
large bone defects (4–7 cm). They successfully treated 3 patients,
with defects in the tibia, humerus, and ulna, respectively. A subse-
quent study conﬁrmed healing of the defects after 6–7 years [33].
The next level of complexity involves culturing the MSCs for
several days or weeks on a biomaterial, which is then implanted
into the bone defect.
Morishita et al. [34] used this technique successfully in 3
patients with benign bone tumours. BM MSCs were allowed to
proliferate for 2 weeks then cultured on hydroxyapatite granules
for 2 weeks in a medium designed to promote osteoblastic dif-
ferentiation. The construct was then implanted into the defects.
Osteo-integration was satisfactory 29 months later.Meijer et al. [35] reported outcomes in 6 patients with jaw
defects treated using this technique. In biopsies obtained after
4 months, bone formation was  detected in 3 patients but was
induced by the construct in a single patient. The authors pointed out
ogy: Surgery & Research 100 (2014) S107–S112 S111
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he importance of differentiating bone formation induced by cells
rom the border of the defect and bone production by the implanted
ells. Nevertheless, disappearance of the implanted MSCs does not
ule out a key role for these cells in the initial osteo-induction
rocess.
A radically different approach consists in using the patient as his
r her own bioreactor. Warnke et al. [17] successfully reconstructed
 7-cm mandibular defect using a bone and muscle construct that
as previously prepared in vivo. Titanium mesh designed to ﬁt the
one defect was loaded with hydroxyapatite granules coated with
ecombinant human BMP-7 and unconcentrated BM.  This construct
as then implanted into the latissimus dorsi muscle to allow for
ngrowth of vessels from the muscle. After 7 weeks, the construct
as transferred to the bone defect, with an anastomosis of the
uscle vascular pedicle to the external carotid artery. Bone den-
ity increased over time, and new bone was detected throughout
he replacement. Unfortunately, a fracture and an infection devel-
ped, and the patient died of cardiac arrest 15 months after the
mplantation.
.3. Avascular necrosis of the femoral head
Cell therapy undoubtedly has a place in the treatment of avascu-
ar femoral head necrosis, as re-inhabitable matrix persists within
he necrotic bone. Hernigou et al. [36] reported a decrease in
he MSC  population within the proximal femurs of patients with
lucocorticoid-induced femoral head necrosis. Avascular necro-
is can be viewed as a stromal disease, suggesting that injection
r implantation of BM or MSCs may  hold therapeutic potential.
his hypothesis was conﬁrmed [37] in a study of 534 hips with
arly stage avascular necrosis of the femoral head, without loss
f sphericity. Core decompression was combined with grafting of
oncentrated autologous BM aspirated from the iliac-crest. After
–18 years, only 94 hips had required replacement surgery [37].
lso in early avascular femoral head necrosis, a randomised study
f 18 hips showed better 24-month outcomes with core decom-
ression and autologous BM mononuclear cell grafting than with
ore decompression alone [38].
Another study compared 30 hips treated by implantation within
he decompression tunnel of a hydroxyapatite cylinder loaded with
oncentrated BM mononuclear cells to 8 control hips treated with
he cylinder alone [39]. After a mean follow-up of 29 months, the
ecrotic lesion was smaller in the BM group, in which only 3/30
ips showed progression to extensive collapse, compared to 6/9
ontrols. Another randomised trial in early stage avascular femoral
ead necrosis showed signiﬁcantly better outcomes after the injec-
ion of 2 × 106 ex vivo-expanded autologous BM MSCs than after
ore decompression [40].
These studies establish that cell therapy can help to achieve bone
epair. Additional studies with better designs are needed. Technical
hallenges and regulatory requirements contribute to explain the
aucity of published data. Cell therapy indications are recapitulated
n Fig. 3.
. Safety and regulatory requirements
At present, only autologous MSCs are used for bone repair cell
herapy. Intra-operative BM concentration in the operating room
sing small centrifuges and CE-marked kits does not require autho-
isation and is performed under the responsibility of the surgeon.
f the sample is taken out of the operating room for concentration
t another facility, this facility must hold accreditation from the
rench Drug and Healthcare Product Safety Agency (ANSM), which
s the case of cell therapy departments and most French Blood Prod-
ct Units. In a study conducted in France by Hernigou et al. [37] inFig. 3. Summary of bone repair cell therapy indications according to cell type and
use  of a biomaterial.
over 1000 hips treated with concentrated BM,  no procedure-related
complications were recorded.
MSC  culturing for use in humans is classiﬁed in Europe (Euro-
pean Commission 1394/2007) as an ‘advanced therapy medicinal
product’ and can be performed only in facilities that comply with
Good Manufacturing Practices [14]. In France, accreditation by the
Drug and Healthcare Product Safety Agency is required also. Spe-
ciﬁc rules designed to ensure safety and quality must be followed
during harvesting and culturing, and tests must be performed on
the cells produced (sterility, viability, and characteristic membrane
markers) before their implantation. Cases of aneuploidy related to
cell senescence have been reported. Extensively cultured cells are at
risk for senescence, which can impair their self-renewing potential.
However, senescence has been reported only with far longer cultur-
ing times than those used in clinical practice. In addition, no cases of
tumour development have been reported with human MSCs. Tarte
et al. [41] found no evidence of deleterious changes or malignant
transformation of cultured MSCs used in two national multicentre
immune-haematology trials.
However, the immunomodulating effects of MSCs and their
stromal properties (ability to maintain the survival and growth of
associated cells) warrant caution in patients treated for neoplastic
diseases, most notably bone malignancies.
6. The future
Delayed union, nonunion, and osteonecrosis will no doubt be the
leading indications for cell therapy bone repair in everyday practice.
As part of the European REBORNE programme (www.reborne.org),
a multicentre trial was  started in March 2013 to assess the use
of cultured autologous BM cells loaded intra-operatively onto
biphasic calcium-phosphate granules as an alternative to autolo-
gous cancellous bone grafting in patients with delayed union. In
addition, a multicentre trial of cultured autologous MSC injection
in patients with avascular femoral head necrosis is scheduled to
start in 2014.
The development of hydrogel-based solutions for supplying
cells and biomaterials percutaneously can be expected in the future.
The immunosuppressive properties of MSCs may  allow the
transplantation of allogeneic MSCs in various orthopaedic con-
ditions, with the establishment of cell banks for regenerative
medicine. Trials evaluating allogeneic MSCs (Mesoblast) in delayed
union are under way  in Australia.
The next step will consist in medico-economic evaluations of
the beneﬁts of bone repair cell therapy.
The development of tissue engineering techniques for the treat-
ment of large bone defects [42] raises far greater challenges. A
multidisciplinary approach will be required to improve implanted
cell survival and to ensure prompt vessel ingrowth into the bio-
material via careful selection of structure and shape, together with
addition of cytokines and growth factors.
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The regulatory requirements derived from the ﬁeld of med-
cations will have to evolve in accordance with the speciﬁc
haracteristics of cell therapy trials in surgery.
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